Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1152P - Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study

Date

16 Sep 2021

Session

ePoster Display

Presenters

M. Kuruvilla

Citation

Annals of Oncology (2021) 32 (suppl_5): S931-S938. 10.1016/annonc/annonc727

Authors

M.S. Kuruvilla1, I. Syed2, F. Gwadry-Sridhar3, R. Sachdeva4, A. Pencz4, L. Zhan5, K. Hueniken6, D. Patel5, K. Balaratnam5, K. Khan5, B. Grant5, B. Sheffield7, S. Noy8, K.P. Singh8, L. Liu9, M. Ralibuz-Zaman10, B. Davis10, D. Moldaver11, M. Shanahan12, P. Cheema13

Author affiliations

  • 1 Oncology, University of Western Ontario, N6A 5W9 - London/CA
  • 2 Medical Evidence, Astrazeneca, L4Y1M4 - Mississauga/CA
  • 3 Ceo, Pulse Infoframe Inc., N5X4E7 - London/CA
  • 4 Oncology, University of Western Ontario, N6A5W9 - London/CA
  • 5 Oncology, Princess Margaret Hospital, University of Toronto, M5G 2C1 - Toronto/CA
  • 6 Oncology, Princess Margart Hospital, University of Toronto, M5G 2C1 - Toronto/CA
  • 7 Pathology, William Osler Health System, University of Toronto, L6R 3J7 - Brampton/CA
  • 8 Oncology, William Osler Health System - Brampton Civic Hospital, L6R 3J7 - Brampton/CA
  • 9 Biostatistics, Pulse Infoframe Inc., N5X 4E7 - London/CA
  • 10 Epidemiology, Pulse Infoframe Inc., N5X 4E7 - London/CA
  • 11 Health Economics, AstraZeneca, L4Y1M4 - Mississauga/CA
  • 12 Oncology, AstraZeneca, L4Y1M4 - Mississauga/CA
  • 13 William Osler Health System, University of Toronto, Toronto/CA
More

Abstract 1152P

Background

Among patient (pts) who have advanced NSCLC with EGFR driver mutations (EGFRm), most benefit from EGFR tyrosine kinase inhibitors (TKIs). The ADAURA trial showed significant improvement in disease-free survival (DFS) with the addition of the EGFR TKI, osimertinib, in resected early stage (IB-IIIA) EGFRm NSCLC pts. The objective of the POTENT study was to estimate EGFRm prevalence and assess outcomes in resected early stage EGFRm NSCLC in real-world setting in Canada.

Methods

Retrospective chart review was conducted for all adult pts with resected stage IB-IIIA NSCLC diagnosed between Jan 2016 and Dec 2019 at 3 Canadian Cancer Centers. Data on EGFRm status, treatments and clinical outcomes were collected.

Results

Of 440 stage IB-IIIA pts whose tumors had EGFR reflex testing, 95 (22%) were EGFRm. Among pts with EGFRm tumors, mean age was 65 years; 66% were female; among those with known ethnicity, 23% were Asian. Of total, 12.5% with stage IB, 75.0% with stage II, and 82.4% with stage IIIA received adjuvant therapy. Median follow-up time was 29 months. Disease-free survival (DFS) at 2 years was 84.6%, 53.9% and 35.9% for stages IB, II and IIIA, respectively. Number of DFS events at 2 years, median DFS in months, and probability of being alive at 2 years are presented in the table. At time of first recurrence, 85.7% involved distant sites; among distant first recurrences, CNS metastasis occurred in 33% of stage IB, 9% of stage II, and 10% of stage IIIA pts. Table: 1152P

Variable Number of patients (number of DFS events at 2 years) Median DFS in months (95%, CI) Probability of being alive at 2 years (95% CI)
Stage
IB 48 (10) NR (38.2-NE) 0.95 (0.88-1.00)
II 28 (14) 31.5 (17.0-NE) 0.92 (0.83-1.00)
IIIA 17 (12) 18.7 (14.1-NE) 0.87 (0.72-1.00)
II and IIIA combined 45 (26) 22.6 (16.6-38.9) 0.90 (0.82-1.00)
Mutation type
Common mutation 57 (22) 38.2 (32.5-NE) 0.94 (0.88-1.00)
Uncommon mutation 36 (14) 38.9 (21.0-NE) 0.88 (0.78-1.00)
Surgical resection status
R0 91 (35) 38.2 (31.5-NE) 0.92 (0.87-0.98)
R1 1 (1) 17 (NE-NE) NA
R2 1 (0) NR (NE-NE) NA
Adjuvant chemotherapy
Did not receive 51 (14) 40.7 (38.2-NE) 0.90 (0.82-1.00)
Received 42 (22) 31.5 (18.7-NE) 0.95 (0.93-1.00)

Conclusions

Real-world data provide critical context to clinical trials and inform treatment and reimbursement decisions. Pts with resected IB-IIIA EGFRm NSCLC had suboptimal outcomes, despite adjuvant chemotherapy. These results highlight the need for improved therapeutics for this patient population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Paleos Steering Committee.

Funding

Pulse Infoframe Inc. and AstraZeneca.

Disclosure

M.S. Kuruvilla: Financial Interests, Advisory Board: AstraZeneca; Financial Interests, Advisory Board: Bristol Myers Squibb; Financial Interests, Advisory Board: Novartis. I. Syed: Financial Interests, Personal and Institutional, Full or part-time Employment: AstraZeneca. B. Sheffield: Financial Interests, Advisory Board: Amgen; Financial Interests, Advisory Board: AstraZeneca; Financial Interests, Advisory Board: Bayer; Financial Interests, Advisory Board: Biocartis; Financial Interests, Advisory Board: Boehringer Ingelheim; Financial Interests, Advisory Board: Eli Lilly; Financial Interests, Advisory Board: EMD Serono; Financial Interests, Advisory Board: Janssen; Financial Interests, Advisory Board: Merck; Financial Interests, Advisory Board: Novartis; Financial Interests, Advisory Board: Pfizer; Financial Interests, Advisory Board: Roche; Financial Interests, Advisory Board: Thermo Fisher. D. Moldaver: Financial Interests, Full or part-time Employment: AstraZeneca. M. Shanahan: Financial Interests, Full or part-time Employment: AstraZeneca. P. Cheema: Financial Interests, Advisory Board: AstraZeneca; Financial Interests, Advisory Board: Amgen; Financial Interests, Advisory Board: Roche; Financial Interests, Advisory Board: Bristol Myers Squibb; Financial Interests, Advisory Board: Novartis; Financial Interests, Advisory Board: Takeda; Financial Interests, Advisory Board: Pfizer; Financial Interests, Advisory Board: EMD Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.